ライフサイエンスコーパス: transfusion medicine

1 nd erythrocyte under cold storage for use in transfusion medicine.

2 applied to mitigate the transmission risk in transfusion medicine.

3 is considered a major public health issue in transfusion medicine.

4 t or ameliorate this serious complication in transfusion medicine.

5 genotyping to prenatal practice and clinical transfusion medicine.

6 ythrocyte proteins important in neonatal and transfusion medicine.

7 for the fields of erythroid cell biology and transfusion medicine.

8 cted antigens and describes implications for transfusion medicine.

9 es, this may hold important implications for transfusion medicine.

10 g to usher in a new era of safer and precise transfusion medicine.

11 applied to mitigate the transmission risk in transfusion medicine.

12 ) offers exciting clinical opportunities for transfusion medicine.

13 bled that included experts in (1) trauma and transfusion medicine, (2) hematology, (3) maternal-fetal

14 Thus, ALA may be a promising tool in transfusion medicine and in high turnover/high activatio

15 clinical decision support systems (CDSS) in transfusion medicine and other novel ways information te

16 relevant to bleeding and clotting disorders, transfusion medicine and regulation of angiogenesis.

17 Transfusion medicine and treatments of hematopoietic dis

18 onal societies for interventional radiology, transfusion medicine, and anesthesia as well as represen

19 al transfusion safety are a top priority for transfusion medicine, and will depend on a combined appr

20 f we decide that cost-utility thresholds for transfusion medicine are appropriately several fold high

21 EPC-TP likely represents a paradigm shift in transfusion medicine because of its potential to continu

22 bility could be explored for applications in transfusion medicine but also for delivery of nucleic ac

23 Thrombopoietin may be useful in transfusion medicine by: 1) reducing the demand for plat

24 Over the past 60 years, the transfusion medicine community has attained significant

25 ethods were introduced to the blood bank and transfusion medicine community more than a decade ago af

26 database should be of use to members of the transfusion medicine community, those interested in stud

27 In transfusion medicine, DNA-based genotyping is being used

28 tact RBC may have significant application in transfusion medicine, especially for the chronically tra

29 potential advantages as blood substitutes in transfusion medicine, especially in emergency situations

30 Indeed, during its early evolution, transfusion medicine focused almost exclusively on issue

31 AABB and the International Collaboration for Transfusion Medicine Guidelines (the use of leukoreducti

32 AABB and the International Collaboration for Transfusion Medicine Guidelines.

33 cs, neonatology, paediatrics, laboratory and transfusion medicine, haematology, health technology ass

34 Transfusion medicine has become a broad, multidisciplina

35 Implementation of molecular testing for transfusion medicine has been a conservative process and

36 years, the translation of basic research in transfusion medicine has led to development of novel cel

37 Conclusions and Relevance: Research in RBC transfusion medicine has significantly advanced the scie

38 Advances in transfusion medicine have made blood supply safer than e

39 orations between providers with expertise in transfusion medicine, hematology, oncology, transplantat

40 ology, hepatology, radiology, pathology, and transfusion medicine; HSCT advanced-practice providers a

41 The role of transfusion medicine in sickle cell disease is also incr

42 offers an important view into the future of transfusion medicine in the operating room, as well as i

43 ions of healthcare information technology to transfusion medicine include creation of electronic repo

44 tforward but require staff with expertise in transfusion medicine, intensive teamwork, patient-specif

45 The evolution of transfusion medicine into a clinically oriented discipli

46 matologists, transplantation physicians, and transfusion medicine physicians, the data and opinions p

47 bacterial sepsis is a persistent problem in transfusion medicine, posing a greater threat than the c

48 group antigens and antibodies as applied to transfusion medicine practice.

49 is neither monitored nor managed by current transfusion medicine practice; however, the current data

50 s, remains a challenge for hematologists and transfusion medicine providers.

51 he storage and application of neutrophils in transfusion medicine, providing a therapeutic strategy f

52 tologist, neurologist, neuroradiologist, and transfusion medicine specialist); prompt neuro-imaging a

53 th challenging hemostatic complications, and transfusion medicine specialists should collaborate to d

54 rt panel of surgeons, anesthesiologists, and transfusion medicine specialists was recruited internati

55 nternists, pediatricians, hematologists, and transfusion medicine specialists.

56 shed in the College of American Pathologists Transfusion Medicine Survey Sets and in a national surve

57 Thus, it is time to rethink our workflows in transfusion medicine taking advantage of novel technolog

58 In the field of transfusion medicine, the clinical relevance of the meta

59 e spanning infectious diseases, virology and transfusion medicine was assembled to render an expert o

60 The next series of advances in transfusion medicine will complement the current approac

61 tion of healthcare information technology to transfusion medicine will expand, as more institutions e